Search alternatives:
significantly lower » significantly higher (Expand Search)
better decrease » greater decrease (Expand Search), teer decrease (Expand Search), between decreased (Expand Search)
between treated » between trace (Expand Search), between predicted (Expand Search), between estimated (Expand Search)
lower decrease » larger decrease (Expand Search), linear decrease (Expand Search), teer decrease (Expand Search)
Showing 1 - 20 results of 8,324 for search '(( significantly lower decrease ) OR ( significantly ((better decrease) OR (between treated)) ))', query time: 0.52s Refine Results
  1. 1
    Pre-RT and post RT D-dimer levels in associated with prognostic significance.

    Pre-RT and post RT D-dimer levels in associated with prognostic significance. by Huriye Senay Kiziltan (22298378)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 2
    Anion-Assisted Glycosylation of Galactose: A Computational Study

    Anion-Assisted Glycosylation of Galactose: A Computational Study by Kerli Tali (22769704)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Flowchart of patient selection in this study.

    Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 4
    S1 Data -

    S1 Data - by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 5
    The functional network of proteins that differed significantly between CDC-treated and PBS-treated PAH animals.

    The functional network of proteins that differed significantly between CDC-treated and PBS-treated PAH animals. by Ryan C. Middleton (21354246)

    Published 2025
    “…<p>The functional network of proteins that differed significantly between CDC-treated and PBS-treated PAH animals.…”
    Save to List
    Saved in:
  6. 6
    Degeneration Saline group presented with significant decreased final weight in relation to other groups.

    Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

    Published 2025
    Save to List
    Saved in:
  7. 7
    Comparison between the treated and the control group.

    Comparison between the treated and the control group. by Fangjun Qiu (20501352)

    Published 2025
    Save to List
    Saved in:
  8. 8
    Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment.

    Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 9
    Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment.

    Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 10
    Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment.

    Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 11
    Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole.

    Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 12
    Clinical course of patient no.

    Clinical course of patient no. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 13
    Thermoneutrality decreased sepsis survival.

    Thermoneutrality decreased sepsis survival. by Goldia Chan (21453340)

    Published 2025
    Save to List
    Saved in:
  14. 14
    Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n 

    Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Weekly resistance training frequency over time for the DHA and placebo groups combined (n 

    Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups.

    Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Participant demographic and clinical characteristics.

    Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic exercise recommendation on average during chemotherapy.

    Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), randomized controlled trial (RCT).

    Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance training exercise recommendation on average during chemotherapy.

    Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: